|
|
|
| Clinical Effect of Percutaneous Coronary Intervention on Coronary Heart Disease and its Influence on Serum VEGF Level |
| LIU Xu-zeng, YU Xin-dong, LUO Cai-fu, et al |
| Gaoming District People's Hospital of Foshan City,Foshan Guangdong 528500 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical effect of percutaneous coronary intervention (PCI) in the treatment of coronary heart disease (CHD) and its effect on serum vascular endothelial growth factor (VEGF).【Methods】 The clinical data of 92 patients with CHD admitted to our hospital from January 2017 to January 2019 were retrospectively analyzed, and they were divided into observation group and control group according to different treatment methods, with 46 cases in each group. The control group received conservative treatment, while the observation group received PCI on the basis of the control group. The treatment efficiency, cardiac function indexes (LVESD, LVEDD, LVEF, BNP), VEGF levels before and after treatment and the incidence of adverse cardiovascular events were compared between the two groups.【Results】 The effective rate of the observation group was 95.65% (44/46), which was significantly higher than 80.43% (37/46) of the control group (χ2=5.061,P=0.023<0.05). After treatment, LVESD, LVEDd and serum BNP levels in the two groups were lower than those before treatment, and LVEF was higher than that before treatment, and the differences between the two groups were statistically significant (P<0.05). Immediately after operation, the serum VEGF level of the observation group was higher than that of the control group, and the serum VEGF level of the observation group was lower than that of the control group 48 h and 1 week after treatment, the difference was statistically significant (P<0.05). After 3 months of follow-up, the incidence of adverse cardiovascular events in the observation group was 0, which was lower than 15.22% (7/46) of the control group (χ2=5.572,P=0.018<0.05).【Conclusion】 CHD patients with PCI treatment has a good clinical effect, and can reduce the level of VEGF, can better improve the cardiac function of patients, worthy of clinical reference.
|
|
Received: 22 May 2020
|
|
|
|
|
|
[1] 宋伟,朱坤,郑玉水,等.经皮冠状动脉介入术治疗冠心病的疗效及对患者术后心功能恢复的影响[J].医学临床研究,2018,35(7): 1360-1363.
[2] 唐克强,王芳,李腾龙.冠状动脉粥样硬化性心脏病患者经皮冠状动脉介入治疗围手术期出血的相关影响因素及生存状况研究[J].中国现代医学杂志,2017,11(4): 863-867.
[3] 何汉康,朱仕现,李安,等. 血管生成因子水平、平均血小板体积变化与 NSTEMI 患者回旋支病变的关系[J].医学临床研究,2019,36(6): 1192-1194.
[4] 王慧丽.影响冠心病患者经皮冠状动脉介入治疗术后死亡率的危险因素分析[J].中华疾病控制杂志,2017,16(2): 53-57.
[5] 张璇. 冠心病经皮冠状动脉介入术后心脏康复的中医药治疗研究进展[J].中西医结合心脑血管病杂志,2017,3(4): 88-89.
[6] Ujueta F, Weiss EN, Shah B,et al. Effect of percutaneous coronary intervention on survival in patients with stable ischemic heart disease [J].Curr Cardiol Rep,2017, 19(2): 17.
[7] 徐燕.经皮冠状动脉介入治疗对仅单支冠状动脉开放的冠心病心衰患者的疗效及安全性[J].安徽医学,2017,6(2): 86.
[8] 郭莹.经皮冠状动脉介入术对冠心病患者术后血清hs-CRP、MMP-9水平变化的影响[J].医学临床研究,2018,35(1): 126-128.
[9] Guo Y, Yin F, Fan C, et al. Gender difference in clinical outcomes of the patients with coronary artery disease after percutaneous coronary intervention [J].Medicine,2018, 97(30): 63-67. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(8): 1269-1271. |
|
|
|
|
2020, Vol. 37 
